

ゲノム解析研究部 論文(2022年)

【英語論文】

原著論文

1. **Hatakeyama K**, Muramatsu K, Nagashima T, Kawanishi Y, Fukumura R, Ohshima K, Shimoda Y, Kenmotsu H, Mochizuki T, Urakami K, Akiyama Y, Sugino T, Yamaguchi K. Tumor cell enrichment by tissue suspension enables detection of mutations with low variant allele frequency and estimation of germline mutations. *Sci Rep*. 2022 Feb 22;12(1):2953.
2. Furukawa K, **Hatakeyama K**, Terashima M, Nagashima T, Urakami K, Ohshima K, Notsu A, Sugino T, Yagi T, Fujiya K, Kamiya S, Hikage M, Tanizawa Y, Bando E, Kanai Y, Akiyama Y, Yamaguchi K. Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE. *Gastric Cancer*. 2022 Jan;25(1):138-148.
3. Imamura T, Okamura Y, Ohshima K, Uesaka K, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Otsuka S, Ohnami S, Nagashima T, **Hatakeyama K**, Kakuda Y, Sugino T, Urakami K, Akiyama Y, Yamaguchi K. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation. *Cancer Med*. 2022 Apr;11(8):1769-1786.
4. Hino H, Shiomi A, **Hatakeyama K**, Kagawa H, Manabe S, Yamaoka Y, Nagashima T, Ohshima K, Urakami K, Akiyama Y, Yamaguchi K. Comprehensive genetic characterization of rectal cancer in a large cohort of Japanese patients: differences according to tumor location. *J Gastroenterol*. 2022 Jul;57(7):476-485.
5. Shimoda Y, Nagashima T, Urakami K, Kamada F, Nakatani S, Mizuguchi M, Serizawa M, **Hatakeyama K**, Ohshima K, Mochizuki T, Ohnami S, Ohnami S, Kawakami T, Yamazaki K, Murakami H, Kenmotsu H, Shiomi A, Akiyama Y, Yamaguchi K. Development of two 410-cancer-gene panel tests for solid tumors and liquid biopsy based on genome data of 5,143 Japanese cancer patients. *Biomed Res*. 2022;43(4):115-126.
6. Imamura T, Okamura Y, Ohshima K, Uesaka K, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Otsuka S, Ohnami S, Nagashima T, **Hatakeyama K**, Kakuda Y, Sugino T, Urakami K, Akiyama Y, Yamaguchi K. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation. *Cancer Med*. 2022 Apr;11(8):1769-1786.
7. Hino H, Shiomi A, **Hatakeyama K**, Kagawa H, Manabe S, Yamaoka Y, Nagashima T, Ohshima K, Urakami K, Akiyama Y, Yamaguchi K. Comprehensive genetic characterization of rectal cancer in a large cohort of Japanese patients: differences according to tumor location. *J Gastroenterol*. 2022 Jul;57(7):476-485.
8. Ohnami S, Naruoka A, Isaka M, Mizuguchi M, Nakatani S, Kamada F, Shimoda Y, Sakai A, Ohshima K, **Hatakeyama K**, Maruyama K, Ohde Y, Kenmotsu H, Takahashi T, Akiyama Y,

- Nagashima T, Urakami K, Ohnami S, Yamaguchi K. Comparison of genetic susceptibility to lung adenocarcinoma and squamous cell carcinoma in Japanese patients using a novel panel for cancer-related drug-metabolizing enzyme genes. *Sci Rep.* 2022 Oct 26;12(1):17928.
9. Imamura T, Okamura Y, Ohshima K, Uesaka K, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Otsuka S, Ohnami S, Nagashima T, **Hatakeyama K**, Sugino T, Urakami K, Akiyama Y, Yamaguchi K. Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma. *BMC Cancer.* 2022 Oct 5;22(1):1046.
 10. Kagawa H, **Hatakeyama K**, Shiomi A, Hino H, Manabe S, Yamaoka Y, Nagashima T, Ohshima K, Urakami K, Yamaguchi K. Consensus molecular subtyping improves the clinical usefulness of canonical tumor markers for colorectal cancer. *Biomed Res.* 2022;43(6):201-209.

症例報告論文

1. Furukawa K, **Hatakeyama K**, Terashima M, Fujiya K, Tanizawa Y, Bando E, Sugino T, Urakami K, Naito T, Kagawa H, Yamaguchi K. Report of two patients in whom comparisons of the somatic mutation profile were useful for the diagnosis of metastatic tumors. *Surg Case Rep.* 2022 Dec 2;8(1):214.